Johnson & Johnson announced that the European Commission has approved an extension of the Rybrevant marketing authorization to include additional subcutaneous dosing regimens.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Bayer files false advertising suit against J&J and Janssen Biotech
- Johnson & Johnson (JNJ) Stock Flat despite First Co-funding Agreement with Blackstone
- Blackstone, Johnson & Johnson enter co-funding agreement for bleximenib
- Blackstone Life Sciences announces a AML co-funding agreement with J&J
- Johnson & Johnson announces new long-term data from Quasar LTE study